Thank you letter

Novo Nordisk Clinical Trial

NN9535-4191

Dear Sir/Madam

Thank you for participating in the NN9535-4191 trial.

In 35 weeks you have participated in the clinical trial to investigate the safety, effectiveness
and tolerability (a check to see if side effects are bearable) of a glucose lowering product called
semaglutide when injected once-daily.

The clinical trial is expected to involve 704 patients from 10 different countries: United States
of America, Canada, Russia, Malaysia, South Africa, Austria, Czech Republic, Germany, Serbia
and the United Kingdom. Thanks to your participation in this trial we have obtained valuable
information about the effect, safety and how semaglutide is tolerated in the body.

You are always welcome to address any questions you may have and if you are interested in
the trial results [and the treatment you have received]. The trial results will be available at the
web sites novonordisk-trials.com or Clinicaltrials.gov and/or clinicaltrialsregister.eu, at the
earliest [approx October/2017].

We are very grateful for your efforts during the trial. Your participation in the trial has been a
valuable contribution to clinical research, which will give us a better understanding in our
continuous endeavour to improve the treatment of Type 2 diabetes.

Yours sincerely,

Signature Date .
Trial physician/investigator

Version 1.0_MY_EN 25-Mar-2015